News

The EORTC has joined forces with Cancer Research UK, the National Institute for Health Research Cancer Research Network (NCRN), and the United States National Cancer Institute (NCI) to launch an initiative to boost the development of new treatments for patients with rare cancers.

On 24 October 2011, during the third meeting of the European Union Committee of Experts on Rare Diseases (EUCERD), the Recommendations on Quality Criteria for Centres of Expertise for Rare Diseases in Member States were unanimously adopted by the 51-member EUCERD, which has representatives from all 27 EU Member States and from all domains relevant to the fields of rare diseases and orphan drugs, including academia, government, the biopharmaceutical industry and patient organisations.

On 24 September 2011, the 2011 European Multidisciplinary Cancer Congress, held from 23-27 September 2011 in Stockholm, Sweden, organised the first-ever patient advocacy/ethics session dedicated specifically to rare cancers.

At the occasion of the 2011 European Multidisciplinary Cancer Congress held from 23-27 September 2011 in Stockholm, Sweden, the European Action Against Rare Cancers initiative presented its new name and logo, Rare Cancers Europe, as well as its new tagline: Joining forces for action.

EPIRARE is a new project to ’build consensus and synergies for the EU registration of rare disease patients’.

Leading cancer institutes and organisations are combining forces to streamline cross border cancer research in Europe.

From 22 March 2011, EU citizens have access to information on thousands of authorised pharmaceutical clinical trials that are underway in the EU.

At a time when the effects of paediatric oncology research have meant that more and more children survive cancer, its funding is too low and dependent on short-term grant.

February 28th, 2011 is Rare Disease Day. All over the world, rare disease patient organisations and their partners will join forces to create awareness of rare diseases and the millions of people affected by them.

Young patients joined MEPs, experts in paediatric oncology and others to discuss how the rapid rate of progress previously established in childhood cancer is being forcibly arrested by the implementation of recent EU legislation.

An open letter to all those associated with the September 2011 UN Summit (High Level Meeting) on Non-Communicable Diseases

The Battle to Improve Outcomes